Forest’s Recent Launches Boosting Diversity, But Gaining Traction Slowly
This article was originally published in The Pink Sheet Daily
Executive Summary
One exception to the slow-growth outlook is the surprise success of Bystolic (nebivolol), the 16th beta blocker to enter the heavily generalized market, but a product the firm has been able to differentiate more by its tolerability than its efficacy.
You may also be interested in...
Ironwood/Forest Talk Ballpark Pricing For Linzess, Gear Up For Q4 Launch
Locally-acting linaclotide wins FDA approval for two indications – chronic idiopathic constipation and constipation-predominant irritable bowel syndrome – with no limits on length of use, a development that could reinvigorate the GI space.
Carl Icahn’s Partial Victory In Battle For Forest: One Board Seat
Primary care-focused pharma reports that preliminary voting results show former OSI executive Pierre Legault was elected to the Forest board, replacing long-time member and outgoing compensation committee Chairman Dan Goldwasser.
Biopharma Datebook: What’s On The Agenda This Week
Events on tap include release of GWU’s obesity drugs outcomes report, developed at FDA’s request, and the sure-to-be contentious Forest shareholders meeting.